<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-14-22975</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0109582</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Endocrine system</subject><subj-group><subject>Thyroid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Pain management</subject><subj-group><subject>Pain</subject><subj-group><subject>Neuropathic pain</subject></subj-group></subj-group></subj-group><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Nausea</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>The Impact of Prophylactic Dexamethasone on Nausea and Vomiting after Thyroidectomy: A Systematic Review and Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">Prophylactic Dexamethasone for Thyroidectomy</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zou</surname><given-names>Zhenhong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="fn" rid="fn1"><sup>¶</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jiang</surname><given-names>Yuming</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="fn" rid="fn1"><sup>¶</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiao</surname><given-names>Mingjia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zhou</surname><given-names>Ruiyao</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou City, Guangdong Province, China</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Department of Hepatobiliary Surgery, Wuxi People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, China</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Department of General Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Ruian City, Zhejiang Province, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Burney</surname><given-names>Richard E.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Michigan, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">doctor_zry@126.com</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: RZ ZZ MX. Performed the experiments: ZZ YJ. Analyzed the data: ZZ YJ. Contributed reagents/materials/analysis tools: ZZ YJ. Contributed to the writing of the manuscript: RZ MX.</p></fn>
<fn id="fn1" fn-type="other"><p>¶ These authors are co-first authors on this work.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>16</day><month>10</month><year>2014</year></pub-date>
<volume>9</volume>
<issue>10</issue>
<elocation-id>e109582</elocation-id>
<history>
<date date-type="received"><day>23</day><month>5</month><year>2014</year></date>
<date date-type="accepted"><day>6</day><month>9</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Zou et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Background</title>
<p>We carried out a systematic review and meta-analysis to evaluate the impact of prophylactic dexamethasone on post-operative nausea and vomiting (PONV), post-operative pain, and complications in patients undergoing thyroidectomy.</p>
</sec><sec>
<title>Methods</title>
<p>We searched Pubmed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) that evaluated the prophylactic effect of dexamethasone versus placebo with or without other antiemetics for PONV in patients undergoing thyroidectomy. Meta-analyses were performed using RevMan 5.0 software.</p>
</sec><sec>
<title>Results</title>
<p>Thirteen RCTs that considered high quality evidence including 2,180 patients were analyzed. The meta-analysis demonstrated a significant decrease in the incidence of PONV (RR 0.52, 95% CI 0.43 to 0.63, <italic>P</italic>&lt;0.00001), the need for rescue anti-emetics (RR 0.42, 95% CI 0.30 to 0.57, <italic>P</italic>&lt;0.00001), post-operative pain scores (WMD –1.17, 95% CI –1.91 to –0.44, <italic>P</italic> = 0.002), and the need for rescue analgesics (RR 0.65, 95% CI 0.50–0.83, <italic>P</italic> = 0.0008) in patients receiving dexamethasone compared to placebo, with or without concomitant antiemetics. Dexamethasone 8–10<bold> </bold>mg had a significantly greater effect for reducing the incidence of PONV than dexamethasone 1.25–5<bold> </bold>mg. Dexamethasone was as effective as other anti-emetics for reducing PONV (RR 1.25, 95% CI 0.86–1.81, <italic>P</italic> = 0.24). A significantly higher level of blood glucose during the immediate post-operative period in patients receiving dexamethasone compared to controls was the only adverse event.</p>
</sec><sec>
<title>Conclusions</title>
<p>Prophylactic dexamethasone 8–10<bold> </bold>mg administered intravenously before induction of anesthesia should be recommended as a safe and effective strategy for reducing the incidence of PONV, the need for rescue anti-emetics, post-operative pain, and the need for rescue analgesia in thyroidectomy patients, except those that are pregnant, have diabetes mellitus, hyperglycemia, or contraindications for dexamethasone. More high quality trials are warranted to define the benefits and risks of prophylactic dexamethasone in potential patients with a high risk for PONV.</p>
</sec></abstract>
<funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability" xlink:type="simple"><meta-name>Data Availability</meta-name><meta-value>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Post-operative nausea and vomiting (PONV) is a common and distressing complication associated with surgery. The overall incidence of PONV ranges from 20 to 30% in general surgery and up to 80% in high-risk surgical patients when no prophylactic anti-emetic is given <xref ref-type="bibr" rid="pone.0109582-Sonner1">[1]</xref>, <xref ref-type="bibr" rid="pone.0109582-Kranke1">[2]</xref>. For patients undergoing thyroidectomy, PONV is a risk factor for post-operative bleeding <xref ref-type="bibr" rid="pone.0109582-Matory1">[3]</xref>, <xref ref-type="bibr" rid="pone.0109582-Schwartz1">[4]</xref>, and prophylactic anti-emetics may be beneficial.</p>
<p>Previous studies have shown that prophylactic dexamethasone has anti-emetic and analgesic effects. Glucocorticoids are anti-inflammatory and immunosuppressive agents, and dexamethasone may exert its therapeutic actions through central inhibition of prostaglandin synthesis, by decreasing serotonin turnover in the central nervous system, and by influencing the systemic inflammatory response in favor of anti-inflammatory mediators <xref ref-type="bibr" rid="pone.0109582-Fredrikson1">[5]</xref>–<xref ref-type="bibr" rid="pone.0109582-Hong1">[9]</xref>.</p>
<p>A systematic review demonstrated that prophylactic dexamethasone was safe and effective for reducing the incidence of PONV and post-operative pain in patients undergoing laparoscopic cholecystectomy compared to placebo <xref ref-type="bibr" rid="pone.0109582-Karanicolas1">[10]</xref>. In patients undergoing thyroidectomy, a previous meta-analysis demonstrated a significant reduction of PONV in patients treated with a single dose of dexamethasone versus placebo <xref ref-type="bibr" rid="pone.0109582-Chen1">[11]</xref>. However, the relatively small sample size included in this review precluded the authors from drawing definitive conclusions, and the optimal dose and timing of dexamethasone administration, and efficacy of combining dexamethasone with other anti-emetics, remains unclear.</p>
<p>The objective of the current study was to confirm, and continue to investigate the impact of prophylactic corticosteroid administration on PONV, post-operative pain, and complications following thyroidectomy.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<p>This systematic review and meta-analysis is reported in accordance with the recommendations of the PRISMA statement <xref ref-type="bibr" rid="pone.0109582-Moher1">[12]</xref>.</p>
<sec id="s2a">
<title>2.1 Outcome measures</title>
<sec id="s2a1">
<title>2.1.1 Primary outcome measure</title>
<list list-type="order"><list-item>
<p>Incidence of PONV during the immediate 24<bold> </bold>h post-operative period, dichotomized as no nausea versus others; this was evaluated according to a 3-point ordinal scale: no nausea; nausea; retching and/or vomiting</p>
</list-item></list>
</sec><sec id="s2a2">
<title>2.1.2 Secondary outcome measures</title>
<list list-type="order"><list-item>
<p>Post-operative pain scores</p>
</list-item><list-item>
<p>Need for rescue anti-emetic or analgesic agent(s)</p>
</list-item><list-item>
<p>Incidence of steroid-related complications, including hyperglycemia, wound infection, delayed wound healing, headaches, dizziness, facial flushing, constipation, and abdominal pain</p>
</list-item></list>
</sec></sec><sec id="s2b">
<title>2.2 Data collection and analysis</title>
<sec id="s2b1">
<title>2.2.1 Searches</title>
<p>We searched PubMed, Embase, and Cochrane Library databases from their inception to October 1, 2013 using Cochrane Highly Sensitive Search Strategies to identify randomized controlled trials (RCTs) for potential inclusion in our review <xref ref-type="bibr" rid="pone.0109582-Lefebvre1">[13]</xref>. We used the following MeSH terms and keywords: thyroid surgery OR thyroidectomy AND corticosteroid, glucocorticoid, steroid, OR dexamethasone. The search strategy is summarized in <xref ref-type="supplementary-material" rid="pone.0109582.s003">Table S1</xref>. Authors’ names were entered as search terms in the PubMed database to check for additional studies. Trials were also identified using the “related articles” function in PubMed. We hand-searched reference lists from articles identified by the electronic search and from previous meta-analyses. This process was performed iteratively until no additional articles could be identified.</p>
</sec><sec id="s2b2">
<title>2.2.2 Inclusion and Exclusion Criteria</title>
<p>We included RCTs that: evaluated the prophylactic effect of dexamethasone versus placebo without other anti-emetics, dexamethasone versus placebo plus concomitant administration of a different anti-emetic, dexamethasone versus a different anti-emetic, and comparisons using different doses of dexamethasone for PONV in patients undergoing thyroidectomy. The included trials reported at least one of our outcome measures, and clearly reported patient inclusion and exclusion criteria, anesthetic technique, protocols for administration of the experimental drugs, and a definition and evaluation of nausea and vomiting. Studies were excluded if they were not RCTs, included patients who were undergoing other surgical procedures concomitantly, reported insufficient data, or were duplicate studies.</p>
</sec><sec id="s2b3">
<title>2.2.3 Selection of studies</title>
<p>Two reviewers (ZH Zou and YM Jiang) independently examined titles and abstracts to select eligible RCTs. We removed records that were ongoing or unpublished studies, or were published as abstracts or conference proceedings. Where datasets were overlapping or duplicated, only the most recent information was included. We retrieved the full text of potentially relevant studies. Two reviewers (ZH Zou and YM Jiang) independently examined the full text records to determine which studies met the inclusion criteria. We resolved disagreements about selection of studies by discussion and consensus.</p>
</sec><sec id="s2b4">
<title>2.2.4 Data extraction and management</title>
<p>Two reviewers (ZH Zou and YM Jiang) independently extracted data from eligible RCTs including details describing study population, interventions, and outcomes. We resolved disagreements about data extraction by discussion and consensus.</p>
</sec><sec id="s2b5">
<title>2.2.5 Assessment of quality of evidence in included studies</title>
<p>Two reviewers (ZH Zou and YM Jiang) independently assessed RCT quality and risk of bias using tools provided by the Cochrane Collaboration <xref ref-type="bibr" rid="pone.0109582-Higgins1">[14]</xref>. The reviewers examined six domains including sequence generation, allocation concealment, double-blind evaluation (blinding), complete outcome data, selective outcome reporting, and baseline comparability of groups. The risk of bias was categorized as low, high, or unclear. RCTs with high risk of bias in at least three of six domains were not included in the meta-analysis. Baseline comparability of groups was assessed using seven matching criteria: age, sex, history of motion sickness, previous post-operative emesis, anesthetic technique, operation type (partial or total thyroidectomy), and duration of surgery. Baseline incomparability was defined as non-matching in at least three of the seven criteria. We resolved disagreements about quality of evidence by discussion and consensus.</p>
</sec><sec id="s2b6">
<title>2.2.6 Statistical analysis</title>
<p>Statistical analyses were performed using RevMan (ver. 5.0; The Cochrane Collaboration, Oxford, UK) software and STATA (ver. 11.2; STATA Corporation, College Station, TX, USA) software. Weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated for continuous variables, and risk ratios (RRs) with 95% CIs were calculated for dichotomous variables. A random-effects model was used to pool studies with significant heterogeneity, as determined by the chi-squared test (<italic>P</italic>≤0.10) and the inconsistency index (<italic>I<sup>2</sup></italic>≥50%). Potential sources of statistical heterogeneity were explored by carrying out subgroup and sensitivity analyses. Subgroup analyses were performed by stratifying patients according to dose of corticosteroid and timing of dexamethasone administration; sensitivity analyses explored the impact of excluding outlying results. The presence of publication bias was comprehensively assessed using Begg’s funnel plot and Begg’s rank correlation test of asymmetry. Publication bias was thought to be present when the continuity-corrected <italic>Pr</italic>&gt;|<italic>z</italic>| value was ≤0.1 <xref ref-type="bibr" rid="pone.0109582-Begg1">[15]</xref>. The GRADE system was used to summarize the overall quality of evidence <xref ref-type="bibr" rid="pone.0109582-Atkins1">[16]</xref>, <xref ref-type="bibr" rid="pone.0109582-Guyatt1">[17]</xref>.</p>
</sec></sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>3.1 Trial identification</title>
<p>The searches identified 195 articles. We screened titles and abstracts, and 17 were identified as potentially eligible for inclusion. We retrieved the full text articles. After analyzing the full text articles, 4 studies were excluded and 13 RCTs <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref>–<xref ref-type="bibr" rid="pone.0109582-Fujii2">[30]</xref> were found eligible for inclusion according to our criteria for considering studies in this review (<xref ref-type="fig" rid="pone-0109582-g001">Fig. 1</xref>).</p>
<fig id="pone-0109582-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.g001</object-id><label>Figure 1</label><caption>
<title>Flow chart for selecting the trials.</title>
<p>On the basis of the search strategy, 195 articles were identified by the initial search, and 17 required further assessment. Finally, 13 articles were included in this review.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.g001" position="float" xlink:type="simple"/></fig></sec><sec id="s3b">
<title>3.2 Characteristics of included studies</title>
<p>The characteristics of the included studies are shown in <xref ref-type="table" rid="pone-0109582-t001">Table 1</xref>. The 13 eligible RCTs included 2,180 patients who underwent general anesthesia for thyroidectomy. The majority of RCTs included patients classified as American Society of Anesthesiologists (ASA) class I or II. Exclusion criteria were: pregnant women, patients with insulin-dependent diabetes mellitus, obesity, and patients with a high risk for PONV. Dexamethasone was administered intravenously in a single or combination dose ranging from 1.25–18<bold> </bold>mg. Timing of administration varied from 90<bold> </bold>minutes before skin incision to the end of surgery. Controls included placebo, droperidol, granisetron, ondansetron, tropisetron or a combination of these medications. Confounders such as anesthetic technique and rescue analgesics and anti-emetics were standardized within studies (<xref ref-type="table" rid="pone-0109582-t002">Table 2</xref>). Risk of bias was low across all RCTs (<xref ref-type="table" rid="pone-0109582-t003">Table 3</xref>).</p>
<table-wrap id="pone-0109582-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.t001</object-id><label>Table 1</label><caption>
<title>Characteristics of trials included in the meta-analysis.</title>
</caption><alternatives><graphic id="pone-0109582-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Study</td>
<td align="left" rowspan="1" colspan="1">Samplesize</td>
<td align="left" rowspan="1" colspan="1">Interventions</td>
<td align="left" rowspan="1" colspan="1">Studies divided</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Wang1999 <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref></td>
<td align="left" rowspan="1" colspan="1">120</td>
<td align="left" rowspan="1" colspan="1">D 10 mg vs. Droperidol1.25<bold> </bold>mg vs. Placebo, all IVat 1<bold> </bold>minute before induction</td>
<td align="left" rowspan="1" colspan="1">Wang 1999 D 10: D 10 mg vs.Placebo; Wang 1999: D 10 mg vs.Droperidol 1.25 mg</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wang2000 <xref ref-type="bibr" rid="pone.0109582-Wang2">[19]</xref></td>
<td align="left" rowspan="1" colspan="1">225</td>
<td align="left" rowspan="1" colspan="1">D 10 mg vs. D 5 mg vs. D2.5 mg vs. D 1.25 mg vs. Placebo,all IV immediately after induction</td>
<td align="left" rowspan="1" colspan="1">Wang 2000 D 10: D 10 mg vs.Placebo; Wang 2000 D 5: D 5 mg vs.Placebo; Wang 2000 D 2.5: D 2.5 mg vs.Placebo; Wang 2000 D 1.25: D 1.25 mg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lee2001 <xref ref-type="bibr" rid="pone.0109582-Lee1">[20]</xref></td>
<td align="left" rowspan="1" colspan="1">135</td>
<td align="left" rowspan="1" colspan="1">D 8 mg vs. D 5 mg vs. Placebo,all IV before anesthesia</td>
<td align="left" rowspan="1" colspan="1">Lee 2001 D 8: D 10 mg vs.Placebo; Lee 2001 D 5: D 5 mg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fujji2007 <xref ref-type="bibr" rid="pone.0109582-Fujii1">[21]</xref></td>
<td align="left" rowspan="1" colspan="1">75</td>
<td align="left" rowspan="1" colspan="1">D 8 mg vs. D 4 mg vs. Placebo,all IV at the end of surgery</td>
<td align="left" rowspan="1" colspan="1">Fujji 2007 D8: D 8 mg vs.Placebo; Fujji 2007 D4: D 4 mg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Worni2008 <xref ref-type="bibr" rid="pone.0109582-Worni1">[22]</xref></td>
<td align="left" rowspan="1" colspan="1">70</td>
<td align="left" rowspan="1" colspan="1">D 8 mg vs. Placebo, both IVat 45<bold> </bold>minutes before anesthesia</td>
<td align="left" rowspan="1" colspan="1">Worni 2008 D8: D 8 mg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Feroci2010 <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref></td>
<td align="left" rowspan="1" colspan="1">102</td>
<td align="left" rowspan="1" colspan="1">D 8 mg vs. Placebo, both IVat 20<bold> </bold>minutes before induction</td>
<td align="left" rowspan="1" colspan="1">Feroci 2010 D8: D 8 mg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Doksrod2012 <xref ref-type="bibr" rid="pone.0109582-Doksrd1">[24]</xref></td>
<td align="left" rowspan="1" colspan="1">120</td>
<td align="left" rowspan="1" colspan="1">D 0.3 mg/kg vs. D 0.15 mg/kg vs.Placebo, all IV within10 min after induction</td>
<td align="left" rowspan="1" colspan="1">Doksrod 2012 D18: D 0.3 mg/kg vs. Placebo;Doksrod 2012 D9: D 0.15 mg/kg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Song2013 <xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref></td>
<td align="left" rowspan="1" colspan="1">123</td>
<td align="left" rowspan="1" colspan="1">D 10 mg vs. Ramosetron0.3 mg vs. Placebo, both IVimmediately after anesthesia</td>
<td align="left" rowspan="1" colspan="1">Song 2013 D 10: D10: D 10 mg vs.Placebo; Song 2013: D 10 mg vs.Ramosetron 0.3 mg</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Barros2013 <xref ref-type="bibr" rid="pone.0109582-Barros1">[26]</xref></td>
<td align="left" rowspan="1" colspan="1">40</td>
<td align="left" rowspan="1" colspan="1">D 4 mg vs. Placebo, bothIV immediately after induction</td>
<td align="left" rowspan="1" colspan="1">Barros 2013 D4: D 4 mg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Schietroma2013 <xref ref-type="bibr" rid="pone.0109582-Schietroma1">[27]</xref></td>
<td align="left" rowspan="1" colspan="1">328</td>
<td align="left" rowspan="1" colspan="1">D 8 mg vs. Placebo, bothIV at 90<bold> </bold>minutes before skin incision</td>
<td align="left" rowspan="1" colspan="1">Schietroma 2013 D8: D 8 mg vs. Placebo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhou2012 <xref ref-type="bibr" rid="pone.0109582-Zhou1">[28]</xref></td>
<td align="left" rowspan="1" colspan="1">150</td>
<td align="left" rowspan="1" colspan="1">D 8 mg + T 5 mg vs. D 8 mg vs.T 5 mg, all IVimmediately before induction</td>
<td align="left" rowspan="1" colspan="1">Zhou 2012 Tropisetron:D 8 mg + T 5 mg vs.T 5 mg;Zhou 2012: D 8 mg vs. T 5 mg</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bononi2010 <xref ref-type="bibr" rid="pone.0109582-Bononi1">[29]</xref></td>
<td align="left" rowspan="1" colspan="1">562</td>
<td align="left" rowspan="1" colspan="1">D 4 mg +O 4 mg vs.O 4 mg, D IV at inductionand ondansetron IV at15<bold> </bold>minutes before tracheal extubation</td>
<td align="left" rowspan="1" colspan="1">Bononi 2010 Ondansetron:D 4 mg +O 4 mg vs. O 4 mg</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fujji2000 <xref ref-type="bibr" rid="pone.0109582-Fujii2">[30]</xref></td>
<td align="left" rowspan="1" colspan="1">130</td>
<td align="left" rowspan="1" colspan="1">D 8 mg + G 40 ug/kg vs.G 40 ug/kg, both IVimmediately before induction</td>
<td align="left" rowspan="1" colspan="1">Fujji 2000 Granisetron:D 8 mg + G 40 ug/kg vs. G 40 ug/kg</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>IV: intravenous; ASA, American Society of Anesthesiologists; D: dexamethasone; T: tropisetron; O: ondansetron; G: Granisetron.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0109582-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.t002</object-id><label>Table 2</label><caption>
<title>Details of anesthetic technique, and rescue analgesics and anti-emetics in the included trials.</title>
</caption><alternatives><graphic id="pone-0109582-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Study</td>
<td align="left" rowspan="1" colspan="1">Anesthetic technique</td>
<td align="left" rowspan="1" colspan="1">Rescue analgesics</td>
<td align="left" rowspan="1" colspan="1">Rescue antiemetics</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Wang 1999 <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol 2.0–2.5<bold> </bold>mg/kg,glycopyrrolate 0.2<bold> </bold>mg,fentanyl 2.0 ug/kg IVmaintained with 1.0%–2.5%isoflurane in oxygen</td>
<td align="left" rowspan="1" colspan="1">Diclofenac75<bold> </bold>mg IM q12h</td>
<td align="left" rowspan="1" colspan="1">Ondansetron 4<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wang 2000 <xref ref-type="bibr" rid="pone.0109582-Wang2">[19]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol 2.0–2.5<bold> </bold>mg/kg,glycopyrrolate 0.2<bold> </bold>mg,fentanyl 2.0 ug/kg IVmaintained with 1.0%–2.5%isoflurane in oxygen</td>
<td align="left" rowspan="1" colspan="1">Diclofenac75<bold> </bold>mg IM q12h</td>
<td align="left" rowspan="1" colspan="1">Ondansetron 4<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lee 2001 <xref ref-type="bibr" rid="pone.0109582-Lee1">[20]</xref></td>
<td align="left" rowspan="1" colspan="1">Glycopyrrolate 0.2<bold> </bold>mg,fentanyl 2 ug/kg, thiopental5<bold> </bold>mg/kg IV maintainedwith desflurane in oxygen</td>
<td align="left" rowspan="1" colspan="1">Ketorolac 15<bold> </bold>mg IV q6h</td>
<td align="left" rowspan="1" colspan="1">Droperidol 1.25<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fujji 2007 <xref ref-type="bibr" rid="pone.0109582-Fujii1">[21]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol 2<bold> </bold>mg/kg,fentanyl 2 ug/kg, vecuronium0.1<bold> </bold>mg/kg IV maintainedwith 1–3% sevoflurane in oxygen</td>
<td align="left" rowspan="1" colspan="1">Indomethacin50 mg rectally</td>
<td align="left" rowspan="1" colspan="1">Ranitidine 150<bold> </bold>mg orally</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Worni 2008 <xref ref-type="bibr" rid="pone.0109582-Worni1">[22]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol/thiopental,atracurium, isoflurane, orsevoflurane andfentanyl 5–10 ug/kg</td>
<td align="left" rowspan="1" colspan="1">Acetaminophen4<bold> </bold>g/day; second-linemetamizole1g or morphine</td>
<td align="left" rowspan="1" colspan="1">Ondansetron 4<bold> </bold>mg IV; second-line droperidol 0.625<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Feroci 2010 <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol 2<bold> </bold>mg/kg,fentanyl 2 ug/kg,vecuronium 0.1<bold> </bold>mg/kg IVmaintained withsevoflurane in oxygen</td>
<td align="left" rowspan="1" colspan="1">Paracetamol1000<bold> </bold>mg IVq8<bold> </bold>h;second-lineketorolac 30<bold> </bold>mgIV q12h</td>
<td align="left" rowspan="1" colspan="1">Metoclopramide 10<bold> </bold>mg IV; second-line ondansetron 4<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Doksrod 2012 <xref ref-type="bibr" rid="pone.0109582-Doksrd1">[24]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol, fentanyl,vecuronium IV maintainedwith desflurane (4–8%) anditrous oxide (60%) in oxygen</td>
<td align="left" rowspan="1" colspan="1">Oxycodone 5<bold> </bold>mgorally; second-linemetamizole ormorphine 2.5mgIV</td>
<td align="left" rowspan="1" colspan="1">Metoclopramide 20<bold> </bold>mg IV; second-line ondansetron 4<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Song 2013 <xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref></td>
<td align="left" rowspan="1" colspan="1">Remifentanil 1 ug/kg,propofol 1–2<bold> </bold>mg/kg,rocuroniumin 0.9<bold> </bold>mg/kg IV,maintained with desfluranein oxygen–air mixture</td>
<td align="left" rowspan="1" colspan="1">Ketorolac30<bold> </bold>mgIV</td>
<td align="left" rowspan="1" colspan="1">Metoclopramide 10<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Barros 2013 <xref ref-type="bibr" rid="pone.0109582-Barros1">[26]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol, fentanyl 2.0 ug/kg,cisatracurium 0.15<bold> </bold>mg/kg,maintained withsevoflurane in oxygen</td>
<td align="left" rowspan="1" colspan="1">Ketorolac 30<bold> </bold>mgorparecoxib 40<bold> </bold>mg IV</td>
<td align="left" rowspan="1" colspan="1">Ondansetron 4<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Schietroma 2013 <xref ref-type="bibr" rid="pone.0109582-Schietroma1">[27]</xref></td>
<td align="left" rowspan="1" colspan="1">Sodium thiopental5<bold> </bold>mg/kg,atracuriumbesylate 0.5<bold> </bold>mg/kg,maintained with oxygenin air, sevoflurane, andremifentanil hydrochloride</td>
<td align="left" rowspan="1" colspan="1">Ketorolac tromethamine30<bold> </bold>mg IV q6h</td>
<td align="left" rowspan="1" colspan="1">Ondansetron hydrochloride 4<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhou 2012 <xref ref-type="bibr" rid="pone.0109582-Zhou1">[28]</xref></td>
<td align="left" rowspan="1" colspan="1">Propofol 1.5–2.5<bold> </bold>mg/kg,midazolam 0.1–0.2<bold> </bold>mg/kg,fentanyl 1.0–2.0 ug/kg,maintained with 1.0–3.0%sevoflurane in oxygen</td>
<td align="left" rowspan="1" colspan="1">Pethidine 25<bold> </bold>mgIV</td>
<td align="left" rowspan="1" colspan="1">Metoclopramide 10<bold> </bold>mg IV; second-line tropisetron 5<bold> </bold>mg IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bononi 2010 <xref ref-type="bibr" rid="pone.0109582-Bononi1">[29]</xref></td>
<td align="left" rowspan="1" colspan="1">Not stated<sup>a</sup></td>
<td align="left" rowspan="1" colspan="1">Not stated</td>
<td align="left" rowspan="1" colspan="1">Not stated</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fujji 2000 <xref ref-type="bibr" rid="pone.0109582-Fujii2">[30]</xref></td>
<td align="left" rowspan="1" colspan="1">Thiopentone 5 mg/kg,fentanyl 2 ug/kg,vecuronium0.2 mg/kg maintainedwith isoflurane (1.0%–3.0%)and nitrous oxide(66%) in oxygen</td>
<td align="left" rowspan="1" colspan="1">Indomethacin50mg rectally formoderae painand buprenorphiine 0.2 mg IM forsevere pain</td>
<td align="left" rowspan="1" colspan="1">Domperidone retally</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>IV, intravenous; IM, intramuscular; <sup>a</sup>no difference.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0109582-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.t003</object-id><label>Table 3</label><caption>
<title>Quality of evidence in included studies.</title>
</caption><alternatives><graphic id="pone-0109582-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Included studies</td>
<td align="left" rowspan="1" colspan="1">Country</td>
<td align="left" rowspan="1" colspan="1">Sequencegeneration</td>
<td align="left" rowspan="1" colspan="1">Allocationconcealment</td>
<td align="left" rowspan="1" colspan="1">Doubleblinding</td>
<td align="left" rowspan="1" colspan="1">Completeoutcome data</td>
<td align="left" rowspan="1" colspan="1">No selectivereporting</td>
<td align="left" rowspan="1" colspan="1">Baselinecomparability</td>
<td align="left" rowspan="1" colspan="1">Risk ofbias</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Wang 1999 <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref></td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Unclear</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wang 2000 <xref ref-type="bibr" rid="pone.0109582-Wang2">[19]</xref></td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Unclear</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lee 2001 <xref ref-type="bibr" rid="pone.0109582-Lee1">[20]</xref></td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fujii 2007 <xref ref-type="bibr" rid="pone.0109582-Fujii1">[21]</xref></td>
<td align="left" rowspan="1" colspan="1">Japan</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Worni 2008 <xref ref-type="bibr" rid="pone.0109582-Worni1">[22]</xref></td>
<td align="left" rowspan="1" colspan="1">Switzerland</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Feroci 2011 <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref></td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Doksrod 2012 <xref ref-type="bibr" rid="pone.0109582-Doksrd1">[24]</xref></td>
<td align="left" rowspan="1" colspan="1">Norway</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Song 2013 <xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref></td>
<td align="left" rowspan="1" colspan="1">Korea</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Unclear</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Barros 2013 <xref ref-type="bibr" rid="pone.0109582-Barros1">[26]</xref></td>
<td align="left" rowspan="1" colspan="1">Portugal</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Schietroma 2013 <xref ref-type="bibr" rid="pone.0109582-Schietroma1">[27]</xref></td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhou 2012 <xref ref-type="bibr" rid="pone.0109582-Zhou1">[28]</xref></td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Unclear</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bononi 2010 <xref ref-type="bibr" rid="pone.0109582-Bononi1">[29]</xref></td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Unclear</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fujii 2000 <xref ref-type="bibr" rid="pone.0109582-Fujii2">[30]</xref></td>
<td align="left" rowspan="1" colspan="1">Japan</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Adequate</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Low</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s3c">
<title>3.3 Treatment effects</title>
<sec id="s3c1">
<title>3.3.1 Primary outcome</title>
<p><italic>Incidence of PONV: Dexamethasone versus placebo, with or without concomitant anti-emetics -</italic> Data reporting on the incidence of PONV in thyroidectomy patients treated with dexamethasone versus placebo with or without concomitant anti-emetics are described in 11 RCTs <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref>–<xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref>, <xref ref-type="bibr" rid="pone.0109582-Zhou1">[28]</xref>–<xref ref-type="bibr" rid="pone.0109582-Fujii2">[30]</xref>. The meta-analysis demonstrated a significant decrease in the incidence of PONV in patients receiving dexamethasone compared to placebo, with or without concomitant anti-emetics (RR 0.52, 95% CI 0.43 to 0.63, <italic>P</italic>&lt;0.00001; <xref ref-type="fig" rid="pone-0109582-g002">Fig. 2</xref>). There was evidence of significant heterogeneity between studies (<italic>P</italic> = 0.003, <italic>I<sup>2</sup></italic> = 56%). The dose-response gradient may have caused most of the variation between RCTs (<xref ref-type="fig" rid="pone-0109582-g003">Fig. 3</xref>; <xref ref-type="supplementary-material" rid="pone.0109582.s001">Fig.S1</xref>).</p>
<fig id="pone-0109582-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.g002</object-id><label>Figure 2</label><caption>
<title>Incidence of PONV grouped by concomitant anti-emetics.</title>
<p>Eleven studies described the incidence of PONV in thyroidectomy patients treated with dexamethasone versus placebo with or without concomitant anti-emetics (RR 0.52, 95% CI 0.43 to 0.63, <italic>P</italic>&lt;0.00001). There was evidence of significant heterogeneity between studies (<italic>P</italic> = 0.003, <italic>I<sup>2</sup></italic> = 56%).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.g002" position="float" xlink:type="simple"/></fig><fig id="pone-0109582-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.g003</object-id><label>Figure 3</label><caption>
<title>PONV according to dexamethasone dose.</title>
<p>Higher dexamethasone doses (8–10<bold> </bold>mg) were significantly more effective than lower dexamethasone doses (1.25–5<bold> </bold>mg) (<italic>P</italic> = 0.02).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.g003" position="float" xlink:type="simple"/></fig>
<p><italic>Incidence of PONV: Dexamethasone versus a different antiemetic -</italic> Data reporting on the incidence of PONV in thyroidectomy patients treated with dexamethasone versus a different anti-emetic, including droperidol, granisetron, or tropisetron, are described in three RCTs <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref>, <xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref>, <xref ref-type="bibr" rid="pone.0109582-Zhou1">[28]</xref>. The meta-analysis demonstrated no significant difference in the incidence of PONV in patients receiving dexamethasone compared to these different anti-emetics (RR 1.25, 95% CI 0.86–1.81, <italic>P</italic> = 0.24; <xref ref-type="fig" rid="pone-0109582-g004">Fig. 4</xref>). There was no evidence of significant heterogeneity between RCTs (<italic>P</italic> = 0.27, <italic>I<sup>2</sup></italic> = 23%).</p>
<fig id="pone-0109582-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.g004</object-id><label>Figure 4</label><caption>
<title>Comparison of dexamethasone with other anti-emetics.</title>
<p>Three studies described the incidence of PONV in thyroidectomy patients treated with dexamethasone versus other anti-emetics (RR 1.25, 95% CI 0.86–1.81, <italic>P</italic> = 0.24). There was no evidence of significant heterogeneity between RCTs (<italic>P</italic> = 0.27, <italic>I<sup>2</sup></italic> = 23%).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.g004" position="float" xlink:type="simple"/></fig></sec><sec id="s3c2">
<title>3.3.2 Secondary outcomes</title>
<p><italic>Postoperative pain scores and need for rescue analgesia: Dexamethasone versus placebo with or without concomitant anti-emetics</italic> - Data reporting on post-operative pain scores in thyroidectomy patients treated with dexamethasone versus placebo with or without concomitant anti-emetics are described in six RCTs <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref>, <xref ref-type="bibr" rid="pone.0109582-Lee1">[20]</xref>, <xref ref-type="bibr" rid="pone.0109582-Worni1">[22]</xref>, <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref>, <xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref>, <xref ref-type="bibr" rid="pone.0109582-Barros1">[26]</xref>. Pain scores were evaluated based on visual analogue scales (VAS) completed by patients 24<bold> </bold>h post-operatively. Four RCTs <xref ref-type="bibr" rid="pone.0109582-Worni1">[22]</xref>, <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref>, <xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref>, <xref ref-type="bibr" rid="pone.0109582-Barros1">[26]</xref> reported data as means ± standard deviations (SDs); two RCTs <xref ref-type="bibr" rid="pone.0109582-Wang1">[18]</xref>, <xref ref-type="bibr" rid="pone.0109582-Lee1">[20]</xref> reported data as medians (range) converted to estimated means and SDs <xref ref-type="bibr" rid="pone.0109582-Hozo1">[31]</xref>. The meta-analysis demonstrated a significantly lower post-operative VAS score in patients receiving dexamethasone compared to placebo, with or without concomitant anti-emetics (WMD –1.17, 95% CI –1.91 to –0.44, <italic>P</italic> = 0.002; <xref ref-type="fig" rid="pone-0109582-g005">Fig. 5</xref>). There was evidence of significant heterogeneity between RCTs (<italic>P</italic>&lt;0.00001, <italic>I<sup>2</sup></italic> = 94%). The doses of dexamethasone may have caused most of the variation between RCTs. The need for rescue analgesia was significantly less frequent in the patients that received dexamethasone (RR 0.65, 95% CI 0.50–0.83, <italic>P</italic> = 0.0008; <xref ref-type="fig" rid="pone-0109582-g006">Fig. 6</xref>); there was no evidence of significant heterogeneity between RCTs (<italic>P</italic> = 0.25, <italic>I<sup>2</sup></italic> = 25%).</p>
<fig id="pone-0109582-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.g005</object-id><label>Figure 5</label><caption>
<title>VAS post-operative pain score grouped by dexamethasone dose.</title>
<p>Six studies described post-operative pain scores in thyroidectomy patients treated with dexamethasone versus placebo with or without concomitant anti-emetics (WMD –1.17, 95% CI –1.91 to –0.44, <italic>P</italic> = 0.002). There was evidence of significant heterogeneity between RCTs (<italic>P</italic>&lt;0.00001, <italic>I<sup>2</sup></italic> = 94%).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.g005" position="float" xlink:type="simple"/></fig><fig id="pone-0109582-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.g006</object-id><label>Figure 6</label><caption>
<title>Need for rescue analgesics grouped by concomitant anti-emetics.</title>
<p>Six studies described the need for rescue analgesics in thyroidectomy patients treated with dexamethasone versus placebo with or without concomitant anti-emetics (RR 0.65, 95% CI 0.50–0.83, <italic>P</italic> = 0.0008). There was no evidence of significant heterogeneity between RCTs (<italic>P</italic> = 0.25, <italic>I</italic><sup>2</sup> = 25%).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.g006" position="float" xlink:type="simple"/></fig>
<p><italic>Need for rescue anti-emetic: Dexamethasone versus placebo with or without concomitant antiemetics -</italic> Data reporting on the need for rescue anti-emetics in thyroidectomy patients treated with dexamethasone versus placebo with or without concomitant anti-emetics are described in six studies <xref ref-type="bibr" rid="pone.0109582-Wang2">[19]</xref>, <xref ref-type="bibr" rid="pone.0109582-Song1">[25]</xref>–<xref ref-type="bibr" rid="pone.0109582-Zhou1">[28]</xref>, <xref ref-type="bibr" rid="pone.0109582-Fujii2">[30]</xref>. The meta-analysis demonstrated a significant decrease in the need for rescue anti-emetics in patients receiving dexamethasone compared to placebo, with or without concomitant anti-emetics (RR 0.42, 95% CI 0.30 to 0.57, <italic>P</italic>&lt;0.00001; <xref ref-type="fig" rid="pone-0109582-g007">Fig. 7</xref>). There was no evidence of significant heterogeneity between RCTs (<italic>P</italic> = 0.43, <italic>I<sup>2</sup></italic> = 0%).</p>
<fig id="pone-0109582-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.g007</object-id><label>Figure 7</label><caption>
<title>Need for rescue antiemetics grouped by concomitant antiemetics.</title>
<p>Six studies described the need for rescue antiemetics in thyroidectomy patients treated with dexamethasone versus placebo with or without concomitant antiemetics (RR 0.42, 95% CI 0.30 to 0.57, <italic>P</italic>&lt;0.00001). There was no evidence of significant heterogeneity between RCTs (<italic>P</italic> = 0.43, <italic>I<sup>2</sup></italic> = 0%).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.g007" position="float" xlink:type="simple"/></fig>
<p><italic>Incidence of adverse events: Dexamethasone versus placebo with or without concomitant anti-emetics -</italic> Data reporting on blood glucose levels in thyroidectomy patients treated with dexamethasone are described in two RCTs. A significantly higher level of blood glucose was observed in patients receiving dexamethasone compared to controls during the first 8 hours post-operatively <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref>, <xref ref-type="bibr" rid="pone.0109582-Doksrd1">[24]</xref>. No statistical differences in symptomatic transient hypocalcemia and asymptomatic transient hypocalcemia were present <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref>. One RCT <xref ref-type="bibr" rid="pone.0109582-Schietroma1">[27]</xref> reported that dexamethasone administration prevented recurrent laryngeal nerve palsy; however, this effect was not described elsewhere <xref ref-type="bibr" rid="pone.0109582-Feroci1">[23]</xref>. There were no significant differences in the incidences of extrapyramidal signs including headache, dizziness, constipation, and muscle pain, and other adverse events such as wound infection and delayed wound healing, in patients receiving dexamethasone compared to controls.</p>
</sec></sec><sec id="s3d">
<title>3.4 Subgroup analyses</title>
<sec id="s3d1">
<title>Incidence of PONV: Dose of dexamethasone</title>
<p>Subgroup analyses stratified by dose of dexamethasone (range, 1.25 mg to 18<bold> </bold>mg) demonstrated that dexamethasone 4–5<bold> </bold>mg and 8–10<bold> </bold>mg significantly reduced the incidence of PONV compared to controls (1.25–5 mg: RR 0.59, 95% CI 0.44 to 0.79; 8–10<bold> </bold>mg: RR 0.45, 95% CI 0.35–0.57), while dexamethasone 18<bold> </bold>mg did not (RR 0.82, 95% CI 0.59–1.15) (<xref ref-type="fig" rid="pone-0109582-g003">Fig. 3</xref>). Dexamethasone 8–10<bold> </bold>mg had a significantly greater effect for reducing the incidence of PONV than dexamethasone 1.25–5<bold> </bold>mg (1.25–5<bold> </bold>mg RR 0.40, 95% CI 0.28 to 0.55; 8–10<bold> </bold>mg: RR 0.23, 95% CI 0.18–0.31; P = 0.02; <xref ref-type="supplementary-material" rid="pone.0109582.s001">Fig. S1</xref>).</p>
</sec><sec id="s3d2">
<title>Incidence of PONV: Timing of dexamethasone administration</title>
<p>The RCTs included in this review varied with regard to timing of dexamethasone administration. Some patients received dexamethasone 90<bold> </bold>minutes before skin incision, while others received dexamethasone postoperatively. Wang et al <xref ref-type="bibr" rid="pone.0109582-Wang3">[32]</xref> demonstrated that dexamethasone administered before anesthesia was more effective in decreasing early PONV compared to dexamethasone administered after anesthesia. These observations are in accordance with data showing that the onset time of dexamethasone on anti-emesis is approximately 2 hours. In the current study, subgroup analysis stratified by the timing of dexamethasone administration showed that dexamethasone was most effective in preventing PONV when administered before rather than after induction of anesthesia (<italic>P</italic> = 0.0002; <xref ref-type="supplementary-material" rid="pone.0109582.s002">Fig. S2</xref>).</p>
</sec></sec><sec id="s3e">
<title>3.5 Sensitivity analysis</title>
<p>To explore the effects of individual RCTs on the pooled OR estimates, we performed a sensitivity analysis omitting one study at a time. No single RCT significantly affected the overall results of the meta-analysis.</p>
</sec><sec id="s3f">
<title>3.6 Publication bias</title>
<p>Visual inspection of a Funnel plot, Egger's test, and Begg's rank correlation test revealed no significant publication bias (Begg’s rank correlation test, continuity-corrected Pr&gt;|z| &gt;0.1), except for RCTs reporting on the need for rescue anti-emetic in patients receiving dexamethasone versus placebo, with or without concomitant antiemetics (Pr&gt;|z|  = 0.06), (<xref ref-type="supplementary-material" rid="pone.0109582.s004">Table S2</xref>).</p>
</sec><sec id="s3g">
<title>3.7 Quality of evidence</title>
<p>Quality of available evidence from RCTs, which was downgraded by inconsistency (heterogeneity between studies), indirectness (variations in study setting), or publication bias, and upgraded by dose-response gradient, varied from moderate to high (<xref ref-type="table" rid="pone-0109582-t004">Table 4</xref>).</p>
<table-wrap id="pone-0109582-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0109582.t004</object-id><label>Table 4</label><caption>
<title>GRADE evidence.</title>
</caption><alternatives><graphic id="pone-0109582-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0109582.t004" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Outcomes</td>
<td colspan="2" align="left" rowspan="1">Illustrative comparativerisks<xref ref-type="table-fn" rid="nt103">*</xref> (95% CI)</td>
<td align="left" rowspan="1" colspan="1">Relativeeffect(95% CI)</td>
<td align="left" rowspan="1" colspan="1">No ofParticipants(studies)</td>
<td align="left" rowspan="1" colspan="1">Quality of theevidence(GRADE)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Assumed risk</td>
<td align="left" rowspan="1" colspan="1">Corresponding risk</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Placebo</td>
<td align="left" rowspan="1" colspan="1">Dexamethasone</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Dexamethasone</bold><bold>versus placebo (in</bold><bold>addition to other</bold><bold>antiemetics): PONV</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>440 per</bold><bold>1000</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>229 per 1000</bold>(189 to 277)</td>
<td align="left" rowspan="1" colspan="1"><bold>RR 0.52</bold>(0.43 to0.63)</td>
<td align="left" rowspan="1" colspan="1">1860(17 studies)</td>
<td align="left" rowspan="1" colspan="1">⊕⊕⊕⊕<bold> high</bold><xref ref-type="table-fn" rid="nt105">1</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Dexamethasone</bold><bold>versus placebo (in</bold><bold>addition to other</bold><bold>antiemetics): rescue</bold><bold>antiemetics</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>216 per</bold><bold>1000</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>91 per 1000</bold>(65 to 123)</td>
<td align="left" rowspan="1" colspan="1"><bold>RR 0.42</bold>(0.3 to0.57)</td>
<td align="left" rowspan="1" colspan="1">1020(9 studies)</td>
<td align="left" rowspan="1" colspan="1">⊕⊕⊕ <bold>high</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Dexamethasone</bold><bold>comparison of doses:</bold><bold>PONV</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>440 per</bold><bold>1000</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>229 per 1000</bold> (189 to 277)</td>
<td align="left" rowspan="1" colspan="1"><bold>RR 0.52</bold>(0.43 to0.63)</td>
<td align="left" rowspan="1" colspan="1">1860(17 studies)</td>
<td align="left" rowspan="1" colspan="1">⊕⊕⊕⊕<bold> high</bold><sup>2</sup></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Dexamethasone versus</bold><bold>placebo: VAS pain</bold><bold>score</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">The meandexamethasoneversus placebo:vas pain scorein the interventiongroups was<bold>1.17 lower</bold>(1.91 to 0.44 lower)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">453(6 studies)</td>
<td align="left" rowspan="1" colspan="1">⊕⊕⊕⊖<bold> moderate</bold><sup>3</sup></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Dexamethasone versus</bold><bold>placebo (in addtion to</bold><bold>other antiemetics):</bold><bold>resuce analgesic</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>256 per</bold><bold>1000</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>167 per 1000</bold>(128 to 213)</td>
<td align="left" rowspan="1" colspan="1"><bold>RR 0.65</bold>(0.5 to0.83)</td>
<td align="left" rowspan="1" colspan="1">638(6 studies)</td>
<td align="left" rowspan="1" colspan="1">⊕⊕⊕⊖<bold> moderate</bold><sup>4</sup></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Dexamethasone versus</bold><bold>a different</bold><bold>antiemetic: PONV</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>256 per</bold><bold>1000</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>320 per 1000</bold>(220 to 463)</td>
<td align="left" rowspan="1" colspan="1"><bold>RR 1.25</bold>(0.86 to1.81)</td>
<td align="left" rowspan="1" colspan="1">260(3 studies)</td>
<td align="left" rowspan="1" colspan="1">⊕⊕⊕⊕ <bold>high</bold></td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt103"><label/><p>*The basis for the <bold>assumed risk</bold> (e.g. the median control group risk across studies) is provided in footnotes. The <bold>corresponding risk</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI). <bold>CI:</bold> Confidence interval; <bold>RR:</bold> Risk ratio.</p></fn><fn id="nt104"><label/><p>GRADE Working Group grades of evidence. <bold>High quality:</bold> Further research is very unlikely to change our confidence in the estimate of effect. <bold>Moderate quality:</bold> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <bold>Low quality:</bold> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <bold>Very low quality:</bold> We are very uncertain about the estimate.</p></fn><fn id="nt105"><label>1</label><p>Although the PONV results demonstrated significant heterogeneity (<italic>P</italic> = 0.003, <italic>I</italic><sup>2</sup> = 56%), it was partly explained by the dose of dexamethasone. <sup>2</sup>Downgraded by not comparing higher dose with lower dose directly, but upgraded by the dose-response gradient. <sup>3</sup>Although there was significant heterogeneity (<italic>P</italic>&lt;0.00001, <italic>I</italic><sup>2</sup> = 94%), it was partly explained by the dose of dexamethasone. <sup>4</sup>Publication bias as <italic>Pr</italic>&gt;|<italic>z</italic>| = 0.06.</p></fn><fn id="nt106"><label/><p>PONV: post-operative nausea and vomiting; VAS: visual analogue scales.</p></fn><fn id="nt107"><label/><p><bold>Patient or population:</bold> patients undergoing thyroidectomy. <bold>Settings:</bold> evidence from China, Japan, Korea, Italy, Switzerland, Norway, Portugal. <bold>Intervention:</bold> dexamethasone. <bold>Comparison:</bold> placebo.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4">
<title>Discussion</title>
<p>PONV is a common and distressing complication for patients undergoing thyroidectomy; therefore, prophylactic anti-emetics may be beneficial. An optimal anti-emetic regimen should be capable of decreasing the incidence of PONV without increasing the risk for adverse events. However, most of the currently used anti-emetics, including anti-histamines, butyrophenones, and dopamine receptor antagonists cause occasional undesirable adverse events, such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations, and extrapyramidal signs <xref ref-type="bibr" rid="pone.0109582-Watcha1">[33]</xref>. 5-HT3 antagonists are effective for preventing and treating PONV in patients undergoing various types of surgery <xref ref-type="bibr" rid="pone.0109582-Kovac1">[34]</xref>. However, the use of prophylactic anti-emetic therapy with 5-HT3 antagonists has been criticized for being too expensive <xref ref-type="bibr" rid="pone.0109582-White1">[35]</xref>.</p>
<p>Our meta-analysis of 13 RCTs demonstrated that prophylactic dexamethasone is effective in reducing the incidence of PONV, post-operative pain scores, and the need for rescue analgesia and anti-emetics compared to placebo administered with or without contaminant anti-emetics in patients undergoing thyroidectomy. In addition, our findings showed that dexamethasone is as effective as other anti-emetics for reducing PONV in this patient population. However, the benefits of administering dexamethasone as a more cost-effective anti-emetic and efficacious analgesic drug<sup>35</sup> should be weighed against the potential side effects. Our study indicated that dexamethasone administration is associated with an increase in blood glucose during the immediate post-operative period, but with no other serious adverse events.</p>
<p>For optimal dose and timing of dexamethasone administration, subgroup analyses showed that higher doses of dexamethasone (8–10<bold> </bold>mg) are more effective than lower doses (1.5–5<bold> </bold>mg), and dexamethasone is most effective in preventing PONV when administered before rather than after induction of anesthesia.</p>
<p>In terms of populations eligible for treatment, the RCTs in the current study mostly included healthy patients, and excluded pregnant women, patients with insulin-dependent diabetes mellitus, those who were obese, and patients with a high risk for PONV. As such, the impact of prophylactic dexamethasone on outcomes in high-risk patients is not known. A larger sample size and well-performed RCTs including high risk patients are required for further investigations.</p>
<p>This review has several limitations. First, data reporting on the effects of prophylactic dexamethasone on post-operative pain scores and need for rescue analgesics in thyroidectomy patients were limited by substantial heterogeneity and publication bias, respectively. Second, the studies in this systematic review included patients across various age groups receiving dexamethasone according to very different protocols.</p>
</sec><sec id="s5">
<title>Conclusion</title>
<p>The present meta-analysis shows that prophylactic dexamethasone is safe and effective for reducing the incidence of PONV, post-operative pain, and the need for rescue analgesia and anti-emetics in thyroidectomy patients. Prophylactic dexamethasone 8–10<bold> </bold>mg administered before induction of anesthesia should be recommended for patients undergoing thyroidectomy except for those that are pregnant, have diabetes mellitus, hyperglycaemia or contraindications for corticosteroids. More high quality trials are warranted to define the benefits and risks of prophylactic dexamethasone in potential patients with high risk for PONV.</p>
</sec><sec id="s6">
<title>Supporting Information</title>
<supplementary-material id="pone.0109582.s001" mimetype="image/tiff" xlink:href="info:doi/10.1371/journal.pone.0109582.s001" position="float" xlink:type="simple"><label>Figure S1</label><caption>
<p><bold>Incidence of PONV stratified according to dexamethasone dose: 8–10 mg and 1.25–5 mg.</bold></p>
<p>(TIF)</p>
</caption></supplementary-material><supplementary-material id="pone.0109582.s002" mimetype="image/tiff" xlink:href="info:doi/10.1371/journal.pone.0109582.s002" position="float" xlink:type="simple"><label>Figure S2</label><caption>
<p><bold>Incidence of PONV stratified by timing of dexamethasone administration.</bold></p>
<p>(TIF)</p>
</caption></supplementary-material><supplementary-material id="pone.0109582.s003" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0109582.s003" position="float" xlink:type="simple"><label>Table S1</label><caption>
<p><bold>Search strategy from its inception to October 1, 2013.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material><supplementary-material id="pone.0109582.s004" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0109582.s004" position="float" xlink:type="simple"><label>Table S2</label><caption>
<p><bold>Begg’s rank correlation test for publication bias.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material><supplementary-material id="pone.0109582.s005" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0109582.s005" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p><bold>PRISMA 2009 Checklist.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pone.0109582-Sonner1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sonner</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Hynson</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Katz</surname><given-names>JA</given-names></name> (<year>1997</year>) <article-title>Nausea and vomiting following thyroid and parathyroid surgery</article-title>. <source>J Clin Anesth</source> <volume>9(5)</volume>: <fpage>398</fpage>–<lpage>402</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Kranke1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kranke</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Eberhart</surname><given-names>LH</given-names></name> (<year>2011</year>) <article-title>Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting</article-title>. <source>Eur J Anaesthesiol</source> <volume>28</volume>: <fpage>758</fpage>–<lpage>765</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Matory1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matory</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Spiro</surname><given-names>RH</given-names></name> (<year>1993</year>) <article-title>Wound bleeding after head and neck surgery</article-title>. <source>J Surg Oncol</source> <volume>53(1)</volume>: <fpage>17</fpage>–<lpage>19</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Schwartz1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwartz</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>OH</given-names></name>, <name name-style="western"><surname>Ituarte</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lo Gerfo</surname><given-names>P</given-names></name> (<year>1998</year>) <article-title>Therapeutic controversy: thyroid surgery–the choice</article-title>. <source>J Clin Endocrinol Metab</source> <volume>83(4)</volume>: <fpage>1097</fpage>–<lpage>1105</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Fredrikson1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fredrikson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hursti</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fürst</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Steineck</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Börjeson</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1992</year>) <article-title>Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion</article-title>. <source>Br J Cancer</source> <volume>65</volume>: <fpage>779</fpage>–<lpage>780</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Aapro1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aapro</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Plezia</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Alberts</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>SE</given-names></name>, <etal>et al</etal>. (<year>1984</year>) <article-title>Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide</article-title>. <source>J Clin Oncol</source> <volume>2</volume>: <fpage>466</fpage>–<lpage>471</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Sapolsky1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sapolsky</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Romero</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Munck</surname><given-names>AU</given-names></name> (<year>2000</year>) <article-title>How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions</article-title>. <source>Endocr Rev</source> <volume>21</volume>: <fpage>55</fpage>–<lpage>89</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Hargreaves1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hargreaves</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Costello</surname><given-names>A</given-names></name> (<year>1990</year>) <article-title>Glucocorticoids suppress levels of immunoreactive bradykinin in inflamed tissue as evaluated by microdialysis probes</article-title>. <source>Clin Pharmacol Ther</source> <volume>48</volume>: <fpage>168</fpage>–<lpage>178</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Hong1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Byers</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Oswald</surname><given-names>RJ</given-names></name> (<year>1993</year>) <article-title>Dexamethasone treatment reduces sensory neuropeptides and nerve sprouting reactions in injured teeth</article-title>. <source>Pain</source> <volume>55</volume>: <fpage>171</fpage>–<lpage>181</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Karanicolas1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Karanicolas PJ1, Smith SE, Kanbur B, Davies E, Guyatt GH</collab> (<year>2008</year>) <article-title>The Impact of Prophylactic Dexamethasone on Nausea and Vomiting After Laparoscopic Cholecystectomy A Systematic Review and Meta-Analysis</article-title>. <source>Ann Surg</source> <volume>248(5)</volume>: <fpage>751</fpage>–<lpage>762</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Chen1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Siddiqui</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Tam</surname><given-names>KW</given-names></name> (<year>2012</year>) <article-title>Dexamethasone for prevention of postoperative nausea and vomiting in patients undergoing thyroidectomy: meta-analysis of randomized controlled trials</article-title>. <source>World J Surg</source> <volume>36</volume>: <fpage>61</fpage>–<lpage>68</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Moher1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name> (<year>2010</year>) <collab xlink:type="simple">PRISMA Group</collab> (<year>2010</year>) <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>Int J Surg</source> <volume>8</volume>: <fpage>336</fpage>–<lpage>341</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Lefebvre1"><label>13</label>
<mixed-citation publication-type="other" xlink:type="simple">Lefebvre C, Manheimer E, Glanville J (2011) Chapter 6: searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org" xlink:type="simple">www.cochrane-handbook.org</ext-link>.</mixed-citation>
</ref>
<ref id="pone.0109582-Higgins1"><label>14</label>
<mixed-citation publication-type="other" xlink:type="simple">Higgins JPT, Altman DG, Sterne JAC (2011) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org" xlink:type="simple">www.cochrane-handbook.org</ext-link>.</mixed-citation>
</ref>
<ref id="pone.0109582-Begg1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50(4)</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Atkins1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Atkins</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Best</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Briss</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Eccles</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Falck-Ytter</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <collab xlink:type="simple">GRADE Working Group</collab> (<year>2004</year>) <article-title>Grading quality of evidence and strength of recommendations</article-title>. <source>BMJ</source> <volume>328</volume>: <fpage>1490</fpage>–<lpage>1494</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Guyatt1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guyatt</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gutterman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Baumann</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Addrizzo-Harris</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hylek</surname><given-names>EM</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Grading strength of recommendations and quality of evidence in clinical guidelines</article-title>. <source>Chest</source> <volume>129</volume>: <fpage>174</fpage>–<lpage>181</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Wang1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>YH</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline</article-title>. <source>Anesth Analg</source> <volume>89</volume>: <fpage>200</fpage>–<lpage>203</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Wang2"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>CM</given-names></name> (<year>2000</year>) <article-title>The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study</article-title>. <source>Anesth Analg</source> <volume>91</volume>: <fpage>1404</fpage>–<lpage>1407</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Lee1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>YS</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Prevention of PONV with dexamethasone in female patients undergoing desflurane anesthesia for thyroidectomy</article-title>. <source>Acta Anaesthesiol Sin</source> <volume>39</volume>: <fpage>151</fpage>–<lpage>156</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Fujii1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fujii</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></name> (<year>2007</year>) <article-title>Efficacy of dexamethasone for reducing postoperative nausea and vomiting and analgesic requirements after thyroidectomy</article-title>. <source>Otolaryngol Head Neck Surg</source> <volume>136</volume>: <fpage>274</fpage>–<lpage>277</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Worni1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Worni</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schudel</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Seifert</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Inglin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hagemann</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function</article-title>. <source>Ann Surg</source> <volume>248</volume>: <fpage>1060</fpage>–<lpage>1066</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Feroci1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Feroci</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rettori</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Borrelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lenzi</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ottaviano</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Dexamethasone prophylaxis before thyroidectomy to reduce postoperative nausea, pain, and vocal dysfunction: a randomized clinical controlled trial</article-title>. <source>Head Neck 2011</source> <volume>33</volume>: <fpage>840</fpage>–<lpage>846</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Doksrd1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Doksrød</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sagen</surname><given-names>Ø</given-names></name>, <name name-style="western"><surname>Nøstdahl</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ræder</surname><given-names>J</given-names></name> (<year>2012</year>) <article-title>Dexamethasone does not reduce pain or analgesic consumption after thyroid surgery; a prospective, randomized trial</article-title>. <source>Acta Anaesthesiol Scand</source> <volume>56</volume>: <fpage>513</fpage>–<lpage>519</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Song1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Song</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>C</given-names></name> (<year>2013</year>) <article-title>Effects of ramosetron and dexamethasone on postoperative nausea, vomiting, pain, and shivering in female patients undergoing thyroid surgery</article-title>. <source>J Anesth</source> <volume>27</volume>: <fpage>29</fpage>–<lpage>34</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Barros1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barros</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vale</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Ventura</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Assunção</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Dexamethasone effect on postoperative pain and tramadol requirement after thyroidectomy</article-title>. <source>Pharmacology</source> <volume>91</volume>: <fpage>153</fpage>–<lpage>157</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Schietroma1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schietroma</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cecilia</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Carlei</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sista</surname><given-names>F</given-names></name>, <name name-style="western"><surname>De Santis</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial</article-title>. <source>JAMA Otolaryngol Head Neck Surg</source> <volume>139</volume>: <fpage>471</fpage>–<lpage>478</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Zhou1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Combination of dexamethasone and tropisetron before thyroidectomy to alleviate postoperative nausea, vomiting, and pain: randomized controlled trial</article-title>. <source>World J Surg</source> <volume>36</volume>: <fpage>1217</fpage>–<lpage>1224</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Bononi1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bononi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Amore Bonapasta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vari</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Scarpini</surname><given-names>M</given-names></name>, <name name-style="western"><surname>De Cesare</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Incidence and circumstances of cervical hematoma complicating thyroidectomy and its relationship to postoperative vomiting</article-title>. <source>Head Neck</source> <volume>32</volume>: <fpage>1173</fpage>–<lpage>1177</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Fujii2"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fujii</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>N</given-names></name> (<year>2000</year>) <article-title>Granisetron/dexamethasone combination for the prevention of postoperative nausea and vomiting after thyroidectomy</article-title>. <source>Anaesth Intensive Care</source> <volume>28</volume>: <fpage>266</fpage>–<lpage>269</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Hozo1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hozo</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Djulbegovic</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hozo</surname><given-names>I</given-names></name> (<year>2005</year>) <article-title>Estimating the mean and variance from the median, range, and the size of a sample</article-title>. <source>BMC Med Res Methodol</source> <volume>5</volume>: <fpage>13</fpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Wang3"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Tzeng</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>CS</given-names></name> (<year>2000</year>) <article-title>The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting</article-title>. <source>Anesth Analg</source> <volume>91(1)</volume>: <fpage>136</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Watcha1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Watcha</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>White</surname><given-names>PF</given-names></name> (<year>1992</year>) <article-title>Postoperative nausea and vomiting: its etiology, treatment, and prevention</article-title>. <source>Anesthesiology</source> <volume>77</volume>: <fpage>162</fpage>–<lpage>84</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-Kovac1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kovac</surname><given-names>AL</given-names></name> (<year>2000</year>) <article-title>Prevention and treatment of postoperative nausea and vomiting</article-title>. <source>Drugs</source> <volume>59</volume>: <fpage>213</fpage>–<lpage>43</lpage>.</mixed-citation>
</ref>
<ref id="pone.0109582-White1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>White</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Watcha</surname><given-names>MF</given-names></name> (<year>1993</year>) <article-title>Are new drugs cost-effective for patients undergoing ambulatory surgery</article-title>? <source>Anesthesiology</source> <volume>78(1)</volume>: <fpage>2</fpage>–<lpage>5</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>